Well they did do $66 M this quarter in sales (forgive me if Im off a couple million.) Annualize this and you have a drug that is already north of a 1/4 billion in revenues. Now I know growth isn't going to be what it was projected to be in the near term and quite likely not even i the long term but its clearly headed up. So maybe revenue multiples aren't the best way to value this company because the cost of manufactoring the drug is so much higher than a traditional drug, or maybe just a lower rev multiple would be needed. Right now a 4x Multiple puts us at a billion dollar value. Does anyone think that they can't get to $500M in annualized revenue in the coming years. At that level 1B is only 2X revenues. I think a major pharma, with economies of scale, and all the know how of marketing a drug, could turn a profit on this thing and I don't think $1 B is anywhere out of the realm of realism for valuation. Plus there has to be some value assigned to what I assume is some type of platform technology. Although I only loosely follow DNDN so I'd appreciate other perspectives because if it goes much lower I was thinking it was becoming an attractive target.
Market Data 
Markets 
AI
